Screening for Barrett’s esophagus: Balancing Clinical Value and Cost-effectiveness

Keyphrases

• Cost-effectiveness 100%
• Gastroesophageal Reflux Disease 100%
• Barrett's Esophagus 100%
• Clinical Value 100%
• Clinical Costs 100%
• Esophageal Adenocarcinoma 80%
• Mucosa 40%
• Endoscopic Screening 40%
• Risk Factors 20%
• Comorbidity 20%
• Dysplasia 20%
• Disease Diagnosis 20%
• Obesity 20%
• Male Sex 20%
• Screening Guidelines 20%
• Family History 20%
• Cost Reduction 20%
• Early Diagnosis 20%
• Endoscopy 20%
• Gastrointestinal 20%
• Columnar 20%
• Screening Program 20%
• High-grade Dysplasia 20%
• Endoscopic Surgery 20%
• Extraesophageal Symptoms 20%
• Limited Life Expectancy 20%
• Disease Symptoms 20%
• Screening Modality 20%
• Esophageal Squamous Cell Carcinoma 20%
• Caucasian Race 20%
• Intestinal Metaplasia 20%
• Barrett's Esophagus Screening 20%
• Targeted Screening 20%
• Population Screening 20%
• Barrett's mucosa 20%

Medicine and Dentistry

• Cost-Effectiveness Analysis 100%
• Barrett Esophagus 100%
• Gastroesophageal Reflux 83%
• Esophageal Adenocarcinoma 83%
• Mucosa 50%
• Health Care Cost 33%
• Dysplasia 33%
• Standing 33%
• Precursor 16%
• Early Diagnosis 16%
• Endoscopy 16%
• Family History 16%
• Endoscopic Therapy 16%
• Life Expectancy 16%
• Intestinal Metaplasia 16%
• Comorbidity 16%